share_log

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $13

Benzinga ·  Aug 8, 2023 07:23

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target from $14 to $13.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment